Case Type: Mergers & Acquisitions

Pulmatrix, Inc. (NASDAQ: PULM) related to its merger with Eos SENOLYTIX, Inc. Upon closing of the proposed transaction, Pulmatrix shareholders are expected to own approximately 6% of the combined company.

Solstice Advanced Materials, Inc. (NASDAQ: SOLS) related to its merger with Element Solutions, Inc.

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) related to its sale to Vertex Pharmaceuticals Incorporated. Under the terms of the proposed transaction, Crinetics shareholders are expected to receive $85.00 per share in cash.

Element Solutions, Inc. (NYSE: ESI) related to its sale to Solstice Advanced Materials, Inc. Under the terms of the proposed transaction, Element Solutions shareholders will receive $10.00 in cash and 0.500 shares of Solstice common stock for each Element Solutions share. Upon closing of the proposed transaction, Element Solutions shareholders are expected to own approximately 44% … Read more

ClearOne, Inc. (NYSE: CLRO) related to its merger with Cortigent, Inc. Upon completion of the proposed transaction, ClearOne shareholders will own approximately 12.7% to 14.4% of the outstanding equity in the combined company.

Patrick Industries, Inc. (NASDAQ: PATK) related to its merger with LCI Industries. Upon completion of the proposed transaction, Patrick shareholders will own approximately 52% of the combined company.

LCI Industries (NYSE: LCII) related to its sale to Patrick Industries, Inc. Under the terms of the proposed transaction, LCI shareholders are expected to receive 1.2440 shares of Patrick common stock for each share of LCI common stock.

Iridium Communications Inc. (NASDAQ: IRDM) related to its sale to Rocket Lab Corporation. Under the terms of the proposed transaction, Iridium shareholders are expected to receive $27.00 in cash and a number of shares of Rocket Lab common stock calculated pursuant to an exchange ratio.

Theravance Biopharma, Inc. (NASDAQ: TBPH) related to its sale to Zymeworks Inc. Under the terms of the proposed transaction, Theravance shareholders are expected to receive (i) $176.00 per share in cash and (ii) one contingent value right.

ENDRA Life Sciences Inc. (NASDAQ: NDRA) related to its merger with Noble Africa LLC. Upon closing of the proposed transaction, ENDRA shareholders are expected to own approximately 3% of the combined company.